المؤلفون: Yu. A. Dergunova, V. V. Rodionov, V. V. Kometova, Ю. А. Дергунова, В. В. Родионов, В. В. Кометова

المصدر: Malignant tumours; Том 9, № 3 (2019); 12-19 ; Злокачественные опухоли; Том 9, № 3 (2019); 12-19 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: предикторы, lymphadenectomy, lymph node, lymph node metastases, predictors, лимфаденэктомия, лимфатический узел, метастазы в лимфатических узлах

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/669/460; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой — М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Petrek J.A., Senie R.T., Peters M., Rosen P.P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92 (6):1368-77.; Silberman A.W., McVay C., Cohen J.S., Altura J.F., Brackert S., Sarna G.P. et al. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: Implications for patients with breast cancer. Ann Surg 2004; 240 (1): 1-6.; Wilke L.G., McCall L.M., Posther K.E., Whitworth P.W., Reintgen D.S., Leitch A.M., et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13 (4): 491-500.; Mansel R.E., Fallowfield L., Kissin M., Goyal A., Newcombe R.G., Dixon J.M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006; 98 (9): 599-609.; Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation. N. Engl. Med 2002; 347 (8): 567-575.; Orr R.K. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol 1999; 6109: 116-27.; Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., Whitworth P.W., Blumencranz P.W., et al. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. 2011; 305 (6): 569-575.; Shah-Khan M., Boughey J.C. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial. Cancer Control 2012; 19: 267-276.; Занкин В.В., Родионов В.В., Хайруллин Р.М., Кометова В.В. Гистологическая степень злокачественности эпителиальных опухолей как фактор прогноза их рецидивирования и метастазирования после радикального лечения (взгляд патоморфолога на клинические проблемы). Материалы VI Российской научно-практической конференции «Модниковские чтения». Ульяновск, 2009; 48-50.; Кометова В.В., Родионов В.В., Занкин В.В., Даньшина А.В., Дергунова Ю.А. О корреляции пролиферативного индекса Ki-67 с некоторыми клинико-морфологическими показателями первичной опухоли и регионарных метастазов у пациенток с инвазивным раком молочной железы. Ульяновский медико-биологический журнал. 2014, №4:18-20.; Родионов В.В, Занкин В.В., Аюпова С.Р., Алиева Р.М. Клинико-морфологические предикторы метастатического поражения регионарных лимфоузлов у больных раком молочной железы. Ульяновский медико-биологический журнал. 2012, № 3:85-88.; Родионов В.В., Панченко С.В., Идрисова С.Р., Кометова В.В., Савинов Ю.Г. Номограмма для прогнозирования вероятности метастатического поражения регионарных лимфатических узлов у больных раком молочной железы. Вопросы онкологии. 2015; 61 (3): 435-438.; Kometova V., Rodionov V., Dergunova Y., Rodionova M. The expression and significance of Ki-67 in the primary tumour and lymph nodes metastases in breast cancer patients. Virchow Arch. 2016; 469 (suppl1): 50.; Kometova V., Rodionov V., Idrisova S., Dergunova Y., Rodionova M. Pathological predictors of axillary lymph node metastases in women with breast cancer. Virchow Arch. 2017; 471 (suppl1): 57.; Kometova V., Rodionov V., Rodionova M., Dergunova Y., Panchenko S. New prognostic integrated pathological index in breast cancer patients. Virchow Arch. 2017; 471 (suppl1): 57; Rodionov V., Cometova V., Panchenko S. A new nomogram to predict axillary metastasis in breast cancer patients without axillary surgery. Cancer research. 2015; 75 (9): Р2-01-30; Fisher B., Slack N.H., Bross I.D. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969; 24 (5): 1071-80.; Chua B., Ung O., Taylor R. Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer.ANZ JSurg 2001;71 (12):723-8.; Chen M., Palleschi S., Khoynezhad A. Gecelter G., Marini C.P., Simms H.H. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137 (5): 606-9.; Harden S.P., Neal A.J., Al Nasiri N., Ashley S., Querci della Rovere G. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. Breast 2001; 10 (2): 155-9.; Brenin D.R., Manasseh D.M., El-Tamer M., Troxel A., Schnabel F., Ditkoff B.A., et al. Factors correlating with lymph node metastases in patients with T1 breast cancer. Ann Surg Oncol 2001; 8 (5):432-7.; Anan K., Mitsuyama S., Tamae K., Nishihara K., Iwashita T., Abe Y., et al. Axillary lymph node metastases in patients with small carcinomas of the breast: Is accurate prediction possible? Eur J Surg 2000; 166 (8): 610-5.; Amrut V. Ashturkar, Gayatri S. Pathak., Sanjay D. Deshmukh, Harshal T. Pandave. Factors Predicting the Axillary Lymph Node Metastasis in Breast Cancer: Is Axillary Node Clearance Indicated in Every Breast Cancer Patient? Indian J Surg. 2011; 73 (5): 331-335.; Qiu S.Q., Zeng H.C., Zhang F., Chen C., Huang W.H., Pleijhuis R.G., et al. A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound. Sci Rep 2016; 6: 21196.; Papadatos G., Rangan A. M., Psarianos T., Ung O., Taylor R., Boyages J. Probability of axillary node involvement in patients with tubular carcinoma of the breast. Br J Surg 2001; 88 (6): 860-4.; Wiechmann L., Sampson M., Stempel M., Jacks L.M., Patil S.M., King T., et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009; 16 (10): 2705-10.; Klevesath M. B., Pantel K., Agbaje O., Provenzano E., Wishart G.C., Gough P., et al. Patterns of metastatic spread in early breast cancer. Breast 2013;22 (4):449-54.; Viale G., Zurrida S., Maiorano E., Mazzarol G., Pruneri G., Paganelli G., et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005; 103 (3): 492-500.; Zhang S., Zhang D., Yi S., Gong M., Lu C., Cai Y., et al. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 2017; 8 (2): 2863-73.; Ugras S., Stempel M., Patil S., Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol 2014; 21 (12): 3780-86.; Crabb S. J., Cheang M. C., Leung S., Immonen T., Nielsen T.O., Huntsman D.D., et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 2008; 8 (3): 249-56.; Dihge L., Bendahl P. O., Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg 2017; 104 (11): 1494-505.; Jones T., Neboori H., Wu H. et al. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement? Ann Surg Oncol 2013; 20: 2866-72; https://www.malignanttumors.org/jour/article/view/669

الاتاحة: https://www.malignanttumors.org/jour/article/view/669
https://doi.org/10.18027/2224-5057-2019-9-3-12-19

المؤلفون: V. V. Rodionov, A. A. Midlenko, A. V. Suetin, В. В. Родионов, А. А. Мидленко, А. В. Суетин

المصدر: Creative surgery and oncology; № 1 (2012); 62-64 ; Креативная хирургия и онкология; № 1 (2012); 62-64 ; 2076-3093 ; 2307-0501 ; 10.24060/2076-3093-2012-0-1

مصطلحات موضوعية: смертность, morbidity, survival, mortality, заболеваемость, выживаемость

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/66/66; Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. // Вестник РОНЦ имени Н.Н. Блохина РАМН. – 2005. С. 3–77.; Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006г. // Вестник РОНЦ имени Н.Н. Блохина РАМН. 2008. Т. 19. №2. Прил.1. – С.154.; Иванов В.Г. Эпидемиологические факторы риска, ранняя диагностика рака молочной железы // Практическая Онкология. 2002. Т. 3. №1. С. 1-5.; Кулигина Е.Ш. Эпидемиологические и молекулярные аспекты рака молочной железы // Практическая Онкология. 2010. Т. 11. №4.С. 203-216.; Писарева Л.Ф., Одинцова И.Н. Эпидемиология рака молочной железы в приморском крае // Сибирский онкологический журнал. 2010. №1 (37). С. 50-55.; https://www.surgonco.ru/jour/article/view/66

الاتاحة: https://www.surgonco.ru/jour/article/view/66
https://doi.org/10.24060/2076-3093-2012-0-1-62-64

المؤلفون: M. V. Rodionova, I. K. Vorotnikov, V. V. Rodionov, E. A. Dudko, N. V. Chkhivadze, V. V. Kometova, D. A. Ryabchikov, E. V. Oshkina, A. S. Ozherelyev, T. А. Bogush, М. В. Родионова, И. К. Воротников, В. В. Родионов, Е. А. Дудко, Н. В. Чхиквадзе, В. В. Кометова, Д. А. Рябчиков, Е. В. Ошкина, А. С. Ожерельев, Т. А. Богуш

المصدر: Siberian journal of oncology; № 5 (2015); 102-109 ; Сибирский онкологический журнал; № 5 (2015); 102-109 ; 2312-3168 ; 1814-4861 ; undefined

مصطلحات موضوعية: рак молочной железы, гормонотерапия, Ki67, гормоночувствительность

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/181/183; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial // Lancet Oncol. 2008. Vol. 9 (1). P. 45–53.; Bullwinkel J., Baron-Lühr B., Lüdemann A., Wohlenberg C., Gerdes J., Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells // J. Cell Physiol. 2006. Vol. 206 (3). P. 624–635.; Chang J., Powles T.J., Allred D.C., Ashley S.E., Makris A., Gregory R.K., Osborne C.K., Dowsett M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients // Clin. Cancer Res. 2000. Vol. 6 (2). P. 616–621.; Cuzick J., Dowsett M., Pineda S., Wale C., Salter J., Quinn E., Zabaglo L., Mallon E., Green A.R., Ellis I.O., Howell A., Buzdar A.U., Forbes J.F. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer // J. Clin. Oncol. 2011. Vol. 29 (32). P. 4273–4278. doi:10.1200/JCO.2010.31.2835.; Dowsett M., Smith I., Robertson J., Robison L., Pinhel I., Johnson L., Salter J., Dunbier A., Anderson H., Ghazoui Z., Skene T., Evans A., A’Hern R., Iskender A., Wilcox M., Bliss J. Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer // J. Natl. Cancer Inst. Monogr. 2011. Vol. 2011 (43). P. 120–123. doi:10.1093/jncimonographs/lgr034.; Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., Salter J., Detre S., Hills M., Ashley S., Francis S., Walsh G.; IMPACT Trialists. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival // Clin. Cancer Res. 2005. Vol. 11 (2 Pt 2). 951s–958s.; Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., Dugan M., Borgs M.; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study // Ann. Oncol. 2001. Vol. 12 (11). P. 1527–1532.; Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Jänicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine chemotherapy than tamoxifen for ErbB-1and/or ErbB-2-positive, estrogen receptorpositive primary breast cancer: evidence from a phase III randomized trial // J. Clin. Oncol. 2001. Vol. 19 (18). P. 3808–3816.; Ellis M.J., Tao Y., Luo J., A’Hern R., Evans D.B., Bhatnagar A.S., Chaudri Ross H.A., von Kameke A., Miller W.R., Smith I., Eiermann W., Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics // J. Natl. Cancer Inst. 2008. Vol. 100 (19). P. 1380–1388. doi:10.1093/ jnci/djn309.; Fayanju O.M., Nwaogu I., Jeffe D.B., Margenthaler J.A. Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of elusive prognosticator // Mol. Clin. Oncol. 2015. Vol. 3. P. 775–780.; Gil M.J., Barnadas A., Cirera L., Tusquets I., Muñoz M., Arcusa A., Prieto L., Moreno A., Graupera J., Margeli M. Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial // J. Clin. Oncol. 2004. Vol. 22 (14S). P. 603.; Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., PiccartGebhart M., Thürlimann B., Senn H.J.; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 // Ann. Oncol. 2013. Vol. 24 9. P. 2206–2223. doi:10.1093/annonc/mdt303.; Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. Vol. 144 (5). P. 646–674. doi:10.1016/j.cell.2011.02.013.; Howell A., Harland R.N., Barnes D.M., Baildam A.D., Wilkinson M.J., Hayward E., Swindell R., Sellwood R.A. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment // Cancer Res. 1987. Vol. 47 (1). P. 300–304.; Makris A., Powles T., Allred D.C., Ashley S., Ormerod M.G., Titley J.C., Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response // Breast Cancer Res. Treat. 1998. Vol. 48 (1). P. 11–20.; Romero Q., Bendahl P.-O., Ferno M., Grabau D., Borgquist S. A novel model for Ki67 assessment in breast cancer // Diagnostic pathology. 2014. Vol. 9. P. 118. doi:10.1186/1746-1596-9-118.; Rossi L., Stevens D., Pierga J., Lerebours F., Reyal F., Robain M., Asselain B., Rouzier R. Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population // PloS. One. 2015. Vol. 10 (7): e0132853. doi:10.1371/journal.pone.0132853.; Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., Blum R.H. Primary Systemic Therapy of Breast Cancer // The Oncologist. 2006. Vol. 11 (6). P. 574–589.; Semiglazov V.F., Semiglazov V.V., Ivanov V.G., Bozhok A., Ziltzova E.K., Paltuev R.M., Dashian G.A., Kletzel A., Topuzov E.E., Berstein L. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER-positive breast cancer // J. Clin. Oncol. 2004. Vol. 22 (14S). P. 519.; Von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., Gerber B., Eiermann W., Hilfrich J., Huober J., Jackisch C., Kaufmann M., Konecny G.E., Denkert C., Nekljudova V., Mehta K., Loibl S. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes // J. Clin. Oncol. 2012. Vol. 30 (15). P. 1796–1804. doi:10.1200/JCO.2011.38.8595.; Witteveen A., Vliegen I.M., Sonke G.S., Klaase J.M., IJzerman M.J., Siesling S. Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients // Breast Cancer Res. Treat. 2015. Vol. 152 (3). P. 627–636. doi:10.1007/s10549-015-3490-4.; https://www.siboncoj.ru/jour/article/view/181; undefined

الاتاحة: https://www.siboncoj.ru/jour/article/view/181

المؤلفون: N. V. Den’gina, S. V. Panchenko, V. V. Rodionov, Н. В. Деньгина, С. В. Панченко, В. В. Родионов

المصدر: Malignant tumours; № 1 (2013); 41-46 ; Злокачественные опухоли; № 1 (2013); 41-46 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: адъювантная лучевая терапия, adjuvant radiotherapy

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/22/26; Han M., Partin A. W., Pound C. R., Epstein J. I., Walsh P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. — 2001 Aug; (3): 555-65.; Bottke D., de Reijke T. M., Bartkowiak D., Wiegel T. Salvage radiotherapy in patients with persisting / rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 45:148-157, 2009.; Bolla M., Van H. Poppel, Collette L. et al., Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). The Lancet, vol. 366, no. 9485, pp. 572-578, 2005.; Thompson I. M., Tangen C. M., Paradelo J. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trialю Journal of the American Medical Association, vol. 296, no. 19, pp. 2329-2335, 2006.; Wiegel T., Bottke D., Steiner U. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02 / AUO AP 09 / 95. J Clin Oncol, vol. 27, no.18, pp. 2924-2930, 2009.; Catton C., Gospodarowicz M., Warde P., Panzarella T., Catton P., McLean M., Milosevic M. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001 Apr; 59 (1): 51-60.; Partin A. W., Oesterling J. E. The clinical usefulness of prostate specific antigen: update. — 1994. J Urol. 1994; 152: 1358-68.; Trabulsi E. J., Valicenti R. K., Hanlon A. L. et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. — 2008 Dec; 72 (6): 1298-302.; Fernando P. Secin, Caroline Savage, Claude Abbou et al. The Learning Curve for Laparoscopic Radical Prostatectomy: An International Multicenter Study. J Urol. — 2010, December; 184 (6): 2291-2296; Stephenson A. J., Scardino P. T., Kattan M. W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. — 2007; 25: 2035-41.; Bianco F. J. Jr, Scardino P. T., Eastham J. A. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function («trifecta»). Urology. — 2005; 66: 83-94.; Pound C. R., Partin A. W., Eisenberger M. A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. — 1999; 281: 1591-1597.; Collette L., vsn Poppel H., Bolla M. et al. Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911) Eur J Cancer 41: 2662-2672, 2005.; Gregory P. Swanson, Joseph W. Basler. Prognostic Factors for Failure after Prostatectomy. J Cancer 2011; 2: 1-19.; https://www.malignanttumors.org/jour/article/view/22

الاتاحة: https://www.malignanttumors.org/jour/article/view/22
https://doi.org/10.18027/2224-5057-2013-1-41-46